Hymeglusin is a fungal β-lactone cell wall-targeting antibiotic that irreversibly inhibits cytosolic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase by covalently modifying the active Cys 129 residue of the enzyme. Studies show that hymeglusin can be inhibited by the (2R, 3R)-isomer of β-lactone trans-DU-6622 because this lactone binds to the same site on HMG-CoA synthase as hymeglusin. In addition, hymeglusin suppresses the translation of cWRA in Staphylococcus aureus, which codes for a polypepetide that responds to cell wall inhibition.
1. Tomoda, H., et al. 1999. Biochem. Biophys. Res. Commun. 265: 536-540. PMID: 10558904
2. Tomoda, H., et al. 2004. Biochim. Biophys. Acta. 1636: 22-28. PMID: 14984735
3. Balibar, C.J., et al. 2010. Microbiology. 156: 1372-1383. PMID: 20167623
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.